Work

The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.5022

Authors: Nima Sharifi, Arun Azad, Mona Patel, Jason W.D. Hearn, Michele Wozniak, Fabian Zohren, Jennifer Sugg, Gabriel P. Haas, Arnulf Stenzl, Andrew J. Armstrong

Institutions: Cleveland Clinic, Peter MacCallum Cancer Centre, University of Michigan, Astellas Pharma (United States), Pfizer (United States), University of Tübingen, Duke Medical Center, Duke Cancer Institute

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281703968

Cites:

Cited by:

Related to: 10